Lv11
28 积分 2024-07-15 加入
Type 2 chronic inflammatory diseases: targets, therapies and unmet needs
2小时前
待确认
Equecabtagene Autoleucel in Patients With Relapsed or Refractory Multiple Myeloma
8天前
已完结
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
8天前
已完结
A New Era in the Treatment of Myasthenia Gravis: Six New Medications in The Last 6 Years
10天前
已完结
Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study
28天前
已完结
Clinical response and pathway-specific correlates following TIGIT–LAG3 blockade in myeloma: the MyCheckpoint randomized clinical trial
30天前
已完结
A.R.R.O.W.2: Once- vs twice-weekly carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma
1个月前
已完结
A.R.R.O.W.2: Once- vs twice-weekly carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma
1个月前
已关闭
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma
2个月前
已完结
New insights into the ontogeny, diversity, maturation and survival of long-lived plasma cells
2个月前
已完结
皖公网安备34019202002308
